Frontiers in Nutrition (Nov 2021)

Bornlisy Attenuates Colitis-Associated Colorectal Cancer via Inhibiting GPR43-Mediated Glycolysis

  • Xia Lu,
  • Shuping Qiao,
  • Chen Peng,
  • Wenyue Yan,
  • Zhen Xu,
  • Junxing Qu,
  • Yayi Hou,
  • Shuli Zhao,
  • Ping Chen,
  • Tingting Wang

DOI
https://doi.org/10.3389/fnut.2021.706382
Journal volume & issue
Vol. 8

Abstract

Read online

There is evidence that probiotics have a broad antitumor effect in colorectal cancer (CRC). However, the mechanism remains obscure. Here, we investigated the effect of Bornlisy (BO)-cocktails of three probiotics on colitis-associated colon cancer (CAC) and the underlying mechanism. The treatment of CAC mice with BO resulted in decreased tumor loads as compared with their counterparts. BO also inhibited the proliferation and metastasis of CRC cells in vitro. Furthermore, BO inhibited cell proliferation through downregulating glycolysis. Activating glycolysis reversed the protective role of BO in the CAC mice. Mechanically, BO administration promoted the activation of GPR43, followed by its downstream PLC-PKC-ERK pathway, which led to decreased glucose metabolism. These results suggest that BO may provide an intervention strategy for CRC therapy, while GPR43 is a potential targeting receptor during the BO treatment.

Keywords